» Articles » PMID: 15319865

Persistent Bacteremia Due to Methicillin-resistant Staphylococcus Aureus Infection is Associated with Agr Dysfunction and Low-level in Vitro Resistance to Thrombin-induced Platelet Microbicidal Protein

Abstract

Background: The causes of persistent bacteremia (PB) due to methicillin-resistant Staphylococcus aureus (MRSA) are poorly understood. This investigation examined potential associations between PB with key clinical features and several in vitro bacterial genotypic and phenotypic characteristics, in isolates from 1 institution.

Methods: Pulsed-field gel electrophoresis (PFGE) relatedness, thrombin-induced platelet microbicidal protein (tPMP)-susceptibility phenotype, accessory gene regulator (agr) genotype and functionality (via delta-lysin production), and autolysis phenotypes were assessed in MRSA isolates from the bloodstream of 21 prospectively identified patients with PB (blood cultures positive after > or =7 days of therapy) and of 18 patients with resolving bacteremia (RB) (sterile blood cultures within the first 2-4 days of therapy) due to MRSA.

Results: The 2 groups had comparable baseline characteristics but differed in their clinical courses (e.g., endocarditis was more frequent in patients with PB than in those with RB [43% vs. 0%, respectively; P=.0016]); isolates from patients with PB exhibited higher rates of (1) survival in vitro after exposure to tPMP (22.4+/-14.8% vs. 11.6+/-6.5%, respectively; P=.005); (2) defective delta-lysin production (71.4% vs. 38.9%, respectively; P=.057); (3) non-agr genotype II profile (100% vs. 77.8%, respectively; P=.037); and (4) overrepresentation of a specific PFGE genotype (85.7% vs. 44.4%, respectively; P=.015).

Conclusions: Isolates from patients with PB differed from those in patients with RB, in several in vitro characteristics. Further studies will be necessary to define how these factors might affect clinical outcome.

Citing Articles

Prophage ϕSA169 Enhances Vancomycin Persistence in Methicillin-Resistant (MRSA).

Li Y, Berti A, Abdelhady W, Xiong Y Antibiotics (Basel). 2025; 14(2).

PMID: 40001434 PMC: 11852059. DOI: 10.3390/antibiotics14020191.


Early cytokine signatures and clinical phenotypes discriminate persistent from resolving MRSA bacteremia.

Bergersen K, Zheng Y, Rossetti M, Ruffin F, Pickering H, Parmar R BMC Infect Dis. 2025; 25(1):231.

PMID: 39966757 PMC: 11834594. DOI: 10.1186/s12879-025-10620-3.


: Current perspectives on molecular pathogenesis and virulence.

Girma A Cell Surf. 2025; 13:100137.

PMID: 39758277 PMC: 11699754. DOI: 10.1016/j.tcsw.2024.100137.


Clinical and microbiological characteristics of persistent Staphylococcus aureus bacteremia, risk factors for mortality, and the role of CD4 T cells.

Yang E, Cho Y, Kim E, Chang E, Bae S, Jung J Sci Rep. 2024; 14(1):15472.

PMID: 38969796 PMC: 11226624. DOI: 10.1038/s41598-024-66520-0.


Integrated transcriptomic analysis reveals immune signatures distinguishing persistent versus resolving outcomes in MRSA bacteremia.

Parmar R, Pickering H, Ahn R, Rossetti M, Gjertson D, Ruffin F Front Immunol. 2024; 15:1373553.

PMID: 38846955 PMC: 11153731. DOI: 10.3389/fimmu.2024.1373553.